新辅助化疗结合保肢手术治疗骨肉瘤的临床研究被引量：6

Neoadjuvant chemotherapy combined with limb salvage surgery for osteosarcoma

下载PDF

导出

摘要目的:探讨新辅助化疗结合保肢手术治疗骨肉瘤临床效果。方法:选取2010年5月-2013年5月47例采用新辅助化疗结合保肢手术治疗的骨肉瘤患者为观察组,同期仅实施保肢手术治疗的骨肉瘤患者47例作为对照组,观察比较两组患者治疗后临床效果。结果:观察组患者临床疗效明显高于对照组,组间差异有统计学意义(P<0.05);两组优良率及总有效率比较,观察组均明显优于对照组,组间比较差异有统计学意义(P<0.05);治疗后6个月、1年、3年时间随访两组患者的复发、转移、死亡率,对照组均明显高于观察组,差异有统计学意义(P<0.05)。结论:新辅助化疗结合保肢手术治疗骨肉瘤近远期临床效果显著。 Objective：To investigate clinical effect of neoadjuvant chemotheraPy combined with limb salvage sur-gery for osteosarcoma. Methods：All 47 osteosarcoma Patients were treated by chemotheraPy combined with limb sal-vage surgery in the observation grouP,47 Patients limb salvage surgery as the control grouP. Results：The clinical effi-cacy was significantly higher in observe grouP Patients（P〈0. 05）. After 6 months,1 year,3 years of follow-uP re-laPse,metastasis,mortality was significantly higher than the control grouP（ P 〈0. 05 ）. Conclusion：Neoadjuvant chemotheraPy combined with limb salvage surgery for osteosarcoma short and long term clinical results are effective.

作者黄飞王显勋罗小江

机构地区湖北省中山医院骨科

出处《现代肿瘤医学》 CAS 2015年第13期1911-1913,共3页 Journal of Modern Oncology

基金湖北省自然科学基金资助项目(编号:2013CFB176)

关键词新辅助化疗保肢手术骨肉瘤临床效果 neoadjuvant chemotheraPy limb salvage surgery osteosarcoma clinical effect

分类号 R738.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献11

1E Alvarez Martinez,L Castro Espitia,CM Ardila Medina. Osteosar-coma condrobldstico maxilar : Presentaci6n de un caso chondroblas-tic osteosarcoma of the maxilla : A case report [ J ]. Avances enOdontoestomatologia,2013 ,28(5) :46 -49.
2Lo Schiavo A,Ruocco E,Russo T,et al. Locus minoris resistentiae:An old but still valid way of thinking in medicine[ J]. Clin Derma-tol,2014,32(5) :553 -556.
3Mardekian SK, Tuluc M. Malignant sarcomatous transformation offibrous dysplasia[J]. Head Neck Pathol,2014,8:27.
4Chakraborty S,Das K,Saha S,et al. Nuclear matrix protein SMAR1ation of chromatin hi stone deacetylation [ J ] . J Biol Chem,2014,289(42):29074 -29085.
5Sun Z,Zhang T,Hong H,et al. miR -202 suppresses proliferationand induces apoptosis of osteosarcoma cells by downregulating Gli2[J].Mol Cell Biochem,2014,397(1 -2) :277 -283.
6Kunz P,Fellenberg J,Moskovszky L,et al. Improved survival in os-teosarcoma patients with atypical low vascularization[ J] . Ann SurgOncol,2014,8:26.
7Tiwari A,Jain S,Mehta S,et al. Limb salvage surgery for osteosar-coma :Early results in Indian patients [ J]. Indian J 0rthop,2014,48(3):266-272.
8Choeyprasert W,Natesirinilkul R,Charoenkwan P,et al. Carbopla-tin and doxorubicin in treatment of pediatric osteosarcoma : A 9 -year single institute experience in the Northern Region of Thailand[J]. Asian Pac J Cancer Prev,2013 ,14(2) :1101 -1106.
9Kudawara I,Aoki Y, Ueda T, et al. Neoadjuvant and adjuvantchemotherapy with high - dose ifosfamide,doxorubicin,cisplatinand high - dose methotrexate in non - metastatic osteosarcoma ofthe extremities: A phase II trial in Japan[ J]. J Chemother,2013,25(1) :41 -48.
10Jones KB, Ferguson PC, Lam B, et al. Effects of neoadjuvantchemotherapy on image - directed planning of surgical resectionfor distal femoral osteosarcoma [ J ]. J Bone Joint Surg Am,2012,94(15) :1399 -1405.